Airsculpt Technologies Inc

AirSculpt Technologies reported second quarter 2026 revenue of $42.9 million, a 2.5% decrease from the prior year, and announced a partnership with Tiger Aesthetics to offer AlloClae, a structural adipose tissue allograft for non-surgical body contouring. On a same-center basis excluding London, revenue declined approximately 1% with positive 1% case growth, while average selling price fell 2% to about $12,700. Adjusted EBITDA was $4.9 million, roughly 11.5% of revenue, down $900,000 year-over-year, reflecting a $1.5 million increase in marketing investment. The company reaffirmed its revenue outlook at the lower end of guidance and updated adjusted EBITDA guidance to a range of $12 million to $14 million, citing an additional $5 million in marketing spend for the year. AirSculpt ended the quarter with about $19 million in cash and $5 million available on its revolver, and recently extended its term loan maturity to November 2027.

Tenax Therapeutics and Sionna Therapeutics shares plunged in premarket trading after their respective clinical trials failed, while MarineMax jumped on a reported buyout by Blackstone-owned Safe Harbor Marinas. Tenax stock fell 84.2% after its Phase 3 LEVEL trial of TNX-103 missed its primary endpoint, showing no statistically significant improvement in six-minute walk distance versus placebo with a p-value of 0.63. Sionna shares dropped 92.1% after its Phase 2a trial of SION-719 failed to demonstrate meaningful CFTR function improvement, with a placebo-adjusted sweat chloride change of just -1.0 mmol/L and a p-value of 0.7. MarineMax surged more than 34% after Reuters reported Safe Harbor is close to acquiring the boat retailer for $1.5 billion including debt, or about $53 per share in cash, a substantial premium to Friday's close of $35.68. AAON gained over 10.6% after its second-quarter results apparently beat expectations, while Silence Therapeutics rose 16.2% ahead of a conference call on its Phase 2 SANRECO trial. Dole fell 4.2% after missing second-quarter earnings and revenue estimates, and AirSculpt Technologies dropped 18.4% on weaker quarterly results with revenue down 3% year-over-year.

AirSculpt Technologies reported second-quarter fiscal 2026 non-GAAP earnings per share of $0.01 on revenue of $42.9 million, a 2.5% decline from the prior year. Case volume fell 0.5% to 3,376, and adjusted EBITDA decreased to $4.9 million from $5.8 million a year earlier. The company reaffirmed its full-year 2026 revenue guidance at the lower end of its $151 million to $157 million range, while reducing its adjusted EBITDA outlook to between $12 million and $14 million.